Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
Authors:
- Diletta ValentiniDVDiletta Valentini
- Nicola CotugnoNCNicola Cotugno
- Vittorio ScoppolaVSVittorio Scoppola
- Chiara Di CamilloCCChiara Di Camillo
- Luna ColagrossiLCLuna Colagrossi
- Emma Concetta MannoEMEmma Concetta Manno
- Carlo Federico PernoCPCarlo Federico Perno
- Cristina RussoCRCristina Russo
- Paolo PalmaPPPaolo Palma
- Paolo RossiPRPaolo Rossi
- Alberto VillaniAVAlberto Villani
Open Access
- 28 January 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (3) , 694
Abstract
We aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in young people with Down syndrome (DS), and to compare their humoral immune response with those of the healthy controls (HC). Individuals with DS and HC received the BNT162b2 vaccine. Longitudinal blood samples were collected on the day of vaccination, twenty-one days after the first dose, seven days after the second dose, and six months after the first dose. Both the local and systemic adverse events reported by participants were mild. Pain at the injection site was the most reported local adverse event, while fever was the systemic adverse event. Humoral responses showed a significant increase of anti-S and anti-S trimeric antibody (Ab) levels after both doses of vaccine in both groups. In comparison with HC, Ab levels in individuals with DS were similar at T21, but significantly lower, both in terms anti-S and anti-S trimeric, at T28 (respectively p = 0.0003 and p = 0.0001). At T180 both groups showed a significant reduction of anti-S trimeric Ab levels compared to T28 (p = 0.0004 and p < 0.0001 for DS and HC, respectively). Individuals with DS exhibit a good humoral response to the BNT162b2 vaccine; however, similarly to in HC, the immune response wanes over time.Keywords
This publication has 24 references indexed in Scilit:
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesNew England Journal of Medicine, 2020
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportNew England Journal of Medicine, 2020
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responsesNature, 2020
- Down syndromeNature Reviews Disease Primers, 2020
- Generation of switched memory B cells in response to vaccination in Down syndrome children and their siblingsVaccine, 2015
- Reduced numbers of switched memory B cells with high terminal differentiation potential in Down syndromeEuropean Journal of Immunology, 2014
- Defective B-cell memory in patients with Down syndromeJournal of Allergy and Clinical Immunology, 2014
- Functionality of the pneumococcal antibody response in down syndrome subjectsVaccine, 2013
- Influenza A/H1N1 Vaccination Response Is Inadequate in Down Syndrome Children When the Latest Cut-off Values Are UsedThe Pediatric Infectious Disease Journal, 2012
- IMPAIRED AVIDITY MATURATION AFTER TETANUS TOXOID BOOSTER IN CHILDREN WITH DOWN SYNDROMEThe Pediatric Infectious Disease Journal, 2011